Table 3 Treatment at recurrence
From: Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC
CT 1° drug | Frequency | % |
Cisplatin | 8 | 33.3 |
Carboplatin | 16 | 66.7 |
CT 2° drug | Frequency | % |
Etoposide | 3 | 12.5 |
Paclitaxel | 9 | 37.5 |
Pemetrexed | 3 | 12.5 |
Gemcitabine | 5 | 20.8 |
Vinorelbine | 4 | 16.7 |
CT schedule | Frequency | % |
Weekly | 10 | 41.7 |
Every three weeks | 14 | 58.3 |
Timing of CRT | Frequency | % |
Concomitant | 18 | 75.0 |
Sequential | 6 | 25.0 |
Total RT dose | Mean | Range |
59.5 | 50–66 | |
Timing from CRT to Durvalumab (days) | Mean | Range |
29 | 5–90 |